How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology, and Vaccines

Article

Many CDMOs outsource their nanoparticle supply chain, but in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Content
© 2025 MJH Life Sciences

All rights reserved.